Comparative Pharmacology
Head-to-head clinical analysis: ANTRENYL versus DETROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANTRENYL versus DETROL.
ANTRENYL vs DETROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antrenyl (oxyphenonium bromide) is a quaternary ammonium anticholinergic agent that competitively blocks acetylcholine at muscarinic receptors in smooth muscle, exocrine glands, and the CNS, leading to reduced gastrointestinal motility and secretion.
Competitive muscarinic receptor antagonist, primarily targeting M3 receptors in the bladder, reducing detrusor muscle contractions and increasing bladder capacity.
50 mg orally 3 times daily initially, then adjust to 50-100 mg 3 times daily; 20 mg intramuscularly or intravenously every 4-6 hours as needed.
2 mg orally twice daily; may increase to 4 mg daily in divided doses based on response.
None Documented
None Documented
2-4 hours (terminal), requiring q6-8h dosing for sustained anticholinergic effect
Terminal half-life 6.9 hours (range 4-10 hours) for tolterodine; 7.7 hours (range 5-13 hours) for active 5-hydroxymethyl metabolite; prolonged in hepatic impairment (up to 3-fold).
Renal (80% as unchanged drug and metabolites), biliary/fecal (20%)
Renal: 77% (as metabolites, <1% unchanged); Fecal: 17%; Biliary: minor.
Category C
Category C
Anticholinergic
Anticholinergic